Sage Therapeutics, Inc.
SAGEInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001597553
No open-market purchases or sales by Sage Therapeutics, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $9 in total; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Sage Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Sage Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cola Michael F | Director | – | Jul 31, 2025 | 0 |
| Frates James M | Director | 0 | Jul 31, 2025 | 0 |
| Greene Barry E | President and CEO | 0 | Jul 31, 2025 | 0 |
| Germano Geno J | Director | – | Jul 31, 2025 | 0 |
| Golumbeski George | Director | 0 | Jul 31, 2025 | 0 |
| Barrett Elizabeth A. | Director | 0 | Jul 31, 2025 | 0 |
| Benecchi Christopher | Chief Operating Officer | 0 | Jul 31, 2025 | 0 |
| Federer Jessica | Director | – | Jul 31, 2025 | 0 |
| Shiferman Gregory L. | See Remarks | 0 | Jul 31, 2025 | 0 |
| Quirk Michael C. | See Remarks | 0 | Jul 31, 2025 | 0 |
| Gault Laura | Chief Medical Officer | 34,649 | Feb 14, 2025 | 0 |
| Iguchi Kimi | CFO & Treasurer | 81,405 | Aug 7, 2024 | 0 |
| Cook Anne Marie | SVP, GC & Secretary | 24,040 | Aug 7, 2024 | 0 |
| Jonas Jeffrey M | Director | 128,046 | Jun 11, 2024 | 0 |
| Barrett Elizabeth | Director | 3,000 | Jun 11, 2024 | 0 |
| Paul Steven M | Director | 78,539Indirect | Jan 4, 2024 | 0 |
| Starr Kevin P | Director | – | Jun 16, 2023 | 0 |
| Robichaud Albert | Chief Scientific Officer | 145,553 | Feb 15, 2023 | 0 |
| Kanes Stephen | Chief Medical Officer | 13,471 | Oct 21, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 (view filing) | Aug 9 | 2 days | Barrett ElizabethDirector | PPurchase | +2.00K | $18.64 | +$37.3K | +200.0%3.00K after | |
| May 11, 2023 (view filing) | May 9 | 2 days | Barrett ElizabethDirector | PPurchase | +1.00K | $50.50 | +$50.5K | New position1.00K after | |
| Feb 10, 2023 (view filing)4:42 PM ET | Feb 10 | Same day | Jonas Jeffrey MDirector | SSale | −11.6K | $44.61 | −$519.4K | −8.7%122.0K after | 2 lots |
| Nov 15, 2022 (view filing) | Nov 10 | 5 days | Greene Barry EPresident and CEO | PPurchase | +14.5K | $34.48 | +$500.0K | +44.7%46.9K after | |
| May 9, 2022 (view filing) | May 5 | 4 days | Golumbeski GeorgeDirector | PPurchase | +8.00K | $31.45 | +$251.6K | New position8.00K after | |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Greene Barry EPresident and CEO | PPurchase | +23.6K | $43.15 | +$1.02M | +268.6%32.4K after |